CSL completes Novartis influenza vaccine business acquisition

CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.

news

As foreshadowed in CSL’s release to the Australian Securities Exchange on 31 July, closing of the transaction will allow CSL to integrate the influenza vaccines division with its subsidiary, bioCSL. The combined business will create the second largest influenza vaccine business in the US$4 billion global industry and will have manufacturing plants in the US, UK, Germany and Australia, a commercial presence in approximately 20 countries, a differentiated product portfolio and strong pandemic and pre-pandemic franchises.

Download this release: 
CSL completes Novartis influenza vaccine business acquisition (0.30Mb)


For further information, please contact: 

Investors:
Mark Dehring
Head of Investor Relations
CSL Limited
Phone: +613 93893407
Email:mark.dehring@csl.com.au

Australia Media:
Sharon McHale
Head of Public Affairs
CSL Limited
Phone: +613 93893425
Mobile: +614 0997 8314
Email:sharon.mchale@csl.com.au

US & Europe Media:
Natalie de Vane
Snr. Director Corporate Communications
CSL Behring
Phone: +1 610 878 4468
Email:natalie.devane@cslbehring.com